Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.
Sabrina Francesca LisboaC Vila-VerdeJ RosaD L UlianaC A J SternL J BertoglioL B ResstelF S GuimaraesPublished in: Psychopharmacology (2019)
Drugs augmenting the brain eCB activity can temper the impact of aversive/traumatic experiences by diverse mechanisms depending on the moment of their administration. Considering the pivotal role the extinction process plays in PTSD, the therapeutic potential of these drugs is evident. The sparse number of clinical trials testing these compounds in stress-related disorders is a gap in the literature that needs to be addressed.
Keyphrases
- spinal cord injury
- clinical trial
- endothelial cells
- systematic review
- mental health
- resting state
- white matter
- pluripotent stem cells
- posttraumatic stress disorder
- randomized controlled trial
- social support
- drug induced
- phase ii
- case control
- multiple sclerosis
- functional connectivity
- cerebral ischemia
- brain injury
- study protocol